Carol F Kirkpatrick
Overview
Explore the profile of Carol F Kirkpatrick including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
232
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Willard K, Wilson D, Jackson E, Kirkpatrick C, Cheeley M, Kalra D
J Clin Lipidol
. 2025 Mar;
PMID: 40024840
No abstract available.
2.
Maki K, Kirkpatrick C, Cheeley M, Jacobson T
Curr Atheroscler Rep
. 2024 Nov;
27(1):5.
PMID: 39556289
Purpose Of Review: Statins are first-line pharmacotherapy for the treatment of elevated low-density lipoprotein cholesterol and are generally well-tolerated. However, some patients may experience statin-associated muscle symptoms (SAMS). This paper...
3.
Petersen K, Maki K, Calder P, Belury M, Messina M, Kirkpatrick C, et al.
Br J Nutr
. 2024 Nov;
132(8):1051.
PMID: 39555898
No abstract available.
4.
Petersen K, Maki K, Calder P, Belury M, Messina M, Kirkpatrick C, et al.
Br J Nutr
. 2024 Oct;
132(8):1039-1050.
PMID: 39475012
Epidemiological and clinical trial evidence indicates that -6 polyunsaturated fatty acid (PUFA) intake is cardioprotective. Nevertheless, claims that -6 PUFA intake promotes inflammation and oxidative stress prevail. This narrative review...
5.
Nicholls S, Nelson A, Kastelein J, Ditmarsch M, Hsieh A, Johnson J, et al.
Pharmacol Res Perspect
. 2024 Oct;
12(6):e70010.
PMID: 39425271
Anacetrapib, a cholesteryl ester transfer protein (CETP) inhibitor previously under development, exhibited an usually extended terminal half-life and large food effect and accumulated in adipose tissue. Other CETP inhibitors have...
6.
Soffer D, Marston N, Maki K, Jacobson T, Bittner V, Pena J, et al.
J Clin Lipidol
. 2024 Sep;
18(5):e647-e663.
PMID: 39256087
This National Lipid Association (NLA) Expert Clinical Consensus provides an overview of the physiologic and clinical considerations regarding the role of apolipoprotein B (apoB) measurement to guide clinical care based...
7.
Pagidipati N, Taub P, Ostfeld R, Kirkpatrick C
Nat Rev Cardiol
. 2024 Jul;
22(1):38-46.
PMID: 39020052
Multiple professional societies recommend the Mediterranean and/or Dietary Approaches to Stop Hypertension dietary patterns in their cardiovascular disease prevention guidelines because these diets can improve cardiometabolic health and reduce the...
8.
Agarwala A, Dixon D, Gianos E, Kirkpatrick C, Michos E, Satish P, et al.
J Clin Lipidol
. 2024 Jun;
18(5):e664-e684.
PMID: 38824114
Cardiovascular disease (CVD) is the leading cause of death among women and its incidence has been increasing recently, particularly among younger women. Across major professional society guidelines, dyslipidemia management remains...
9.
Bays H, Kirkpatrick C, Maki K, Toth P, Morgan R, Tondt J, et al.
J Clin Lipidol
. 2024 Apr;
18(3):e320-e350.
PMID: 38664184
Background: This joint expert review by the Obesity Medicine Association (OMA) and National Lipid Association (NLA) provides clinicians an overview of the pathophysiologic and clinical considerations regarding obesity, dyslipidemia, and...
10.
Guarneiri L, Kirkpatrick C, Maki K
Ann Transl Med
. 2024 Feb;
12(1):18.
PMID: 38304910
No abstract available.